Reyataz Lipid Effect Offers Benefit But Not In Lipodystrophy, Cmte. Says
Executive Summary
The favorable lipid profile of Bristol-Myers Squibb's protease inhibitor Reyataz offers HIV patients a clinical benefit over other protease inhibitors, FDA's Antiviral Drugs Advisory Committee agreed May 14